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Abstract 
A series of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides bearing the halogens iodine and bromine 
were synthesised and their binding affinity for the peripheral benzodiazepine binding sites (PBBS) 
in rat kidney mitochondrial membranes were evaluated using [3H]-PK11195. Central 
benzodiazepine receptor (CBR) affinities were also evaluated in rat cortices using 3H-flumazenil to 
determine their selectivity for PBBS over CBR. The tested compounds had PBBS binding affinities 
(IC50) ranging from 7.86 nM to 618 nM, with all compounds showing high selectivity over the CBR 
(CBR IC50 > 5000 nM). Among the 12 compounds tested, those with a diethylamide group were the 
most potent. The highest affinity iodinated PBBS ligand, N,N-diethyl-[5-chloro-2-(4-
iodophenyl)indol-3-yl]glyoxylamide (4c), was radiolabelled with iodine-123. This high affinity and 
selective radioligand may be useful for imaging neurodegeneration, inflammation and tumours 
using single photon emission computed tomography (SPECT). 
Keywords 
Peripheral Benzodiazepine Binding Sites, N,N-dialkyl-2-phenylindol-3-ylglyoxylamides, SPECT, 
Radioiodination.  
1. Introduction 
The Peripheral Benzodiazepine Binding Sites (PBBS) (also termed the Peripheral Benzodiazepine 
Receptors or PBR) are multimeric protein complexes localised mainly on the outer mitochondrial 
membranes of cells in peripheral organs such as the kidney, heart, and steroid producing cells of the 
adrenals, testes and ovaries.1,2 The PBBS are pharmacologically and anatomically different to the 
central benzodiazepine receptors (CBR). Within the normal central nervous system, PBBS are 
expressed at low levels mainly on the choroid plexus, ependymal lining of the ventricles and the 
olfactory bulb.3 Dramatic upregulation of PBBS has been reported in such diverse neuropathologic 
states including Huntington's and Alzheimer's diseases and multiple sclerosis.4,5 Significantly 
enhanced PBBS expression has also been observed in melanoma, breast, prostate, ovarian and glial 
tumours.6,7,8,9  
The development of specific radiotracers for the PBBS has not only contributed to the elucidation 
of the receptor’s biochemical functions, but when imaged with positron emission tomography 
(PET) and single photon emission computed tomography (SPECT), provide a means by which these 
changes can be monitored and correlated to disease.10,11,12, 13 A diverse range of chemical structures 
has been shown to bind to various components of the PBBS. The isoquinoline carboxamide ligand 
PK 11195, the classical 1,4-benzodiazepine, Ro 5-4864 and the imidazopyridine Alpidem (Figure 
1) have been shown to bind to various binding domains of the PBR. [11C]PK 11195 has been used 
to study the PBBS in vivo using PET to detect brain inflammation in humans and to image early 





























Figure 1. Structures of PBBS ligands 
More recently, imidazopyridines15 and pyridazines16 and indoles such FGIN-1-2717,18 (Figure 1) 
have all been reported to bind to the PBBS. Several of these ligands have been radiolabelled with 
iodine-123, for potential imaging using SPECT.16.19,20  
N,N-Dialkyl-2-phenylindolyl-3-glyoxylamides (Figure 2) represent a new class of potent PBBS 
ligands, whose development was based on conformationally constrained analogues of 2-
phenylindole-3-acetamides.21 These compounds offer the potential for radiolabelling with 
radionuclides for both PET and SPECT imaging. In this investigation we synthesised and tested 
several of halogenated derivatives of these systems with the aim of radiolabelling with iodine-123 











Figure 2. Structure of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides 
2. Chemistry 
The N,N-dialkyl-2-phenylindol-3-ylglyoxylamides 4a-l were synthesised following literature 
methods21 for similar compounds and is outlined in scheme 1. Briefly, 2-(4-bromophenyl)indole 2d 
was synthesised in one step, from 4-bromoacetophenone and phenylhydrazine with polyphosphoric 
acid,22 while indoles 2a-c were synthesised in two steps via their phenylhydrazone derivatives 1a-
c.23 The phenylhydrazones were formed by reacting 4-bromo or 4-iodo acetophenone with 
phenylhydrazine or 4-chlorophenylhydrazine hydrochloride, followed by cyclisation by the Fischer 
indole synthesis using polyphosphoric acid. Subsequent acylation using oxalyl chloride gave the 
indolylglyoxylyl chlorides 3a-d, which were aminated using the appropriate amines eg 
dihexylamine, di-n-propylamine, diethylamine, or dimethylamine giving the final N,N-dialkyl-2-










R3 = Br or I
ii
R4 = H or Cl
1a, R3 = I, R4 = Cl
1b, R3 = I, R4 = H



























For 2 and 3
a, R3 = I, R4 = Cl
b, R3 = I, R4 = H
c, R3 = Br, R4 = Cl




Scheme 1. Reagents and conditions (i) Ph-NHNH2 or 4-Cl-PhNHNH2.HCl, ethanol, CH3CO2H; (ii) 
To synthesis 2a-c, polyphosphoric acid; (iii) To synthesise 2d, Ph-NHNH2, polyphosphoric acid; 
(iv) ClCOCOCl, anhydrous ether; (v) NH(alkyl)2, triethylamine, anhy. toluene. 
To prepare the [123I]radiolabelled analogue of 4c, the trimethylstannyl precursor 5, was prepared 
from its corresponding bromo derivative 4k, using hexamethylditin in the presence of a catalytic 
amount of tetrakis(triphenylphoshine)palladium(0) in anhydrous toluene. The radioiodination was 
achieved by an oxidative iododestannylation reaction of 5, and Na123I using per-acetic acid as an 
oxidising agent (Scheme 2). The radioligand, [123I]-N,N-diethyl-[5-chloro-2-(4-iodophenyl)indol-3-
ylglyoxyl]amide was purified and characterised by reverse phase HPLC. The radiochemical yield 





















54k [123I]-4c  
Scheme 2. Preparation of [123I]-N,N-diethyl-[5-chloro-2-(4-iodophenyl)indol-3-ylglyoxyl]amide. 
Reagents and conditions (i) (Sn(CH3)3)2, Pd(PPh3)4, anhydrous toluene, reflux, 8 h; (ii) Na123I, per-
acetic acid, ethanol, acetic acid 
3. Results and Discussion 
The binding affinities (IC50) of the 12 new compounds for the PBBS were determined by measuring 
the displacement of [3H]PK11195 bound to rat kidney mitochondrial membranes. To determine the 
selectivity of the compounds for PBBS versus CBR, CBR binding affinities were determined using 
[3H]Flumazenil on rat cortical membranes. The results of the binding affinities of compounds 4a-l 
for the PBBS and the CBR are shown in Table 1. The compounds examined displayed a medium to 
high affinity for the PBBS, ranging from 7.86 nM to 618 nM. All compounds had high selectivity 
for PBBS over CBR, with all CBR IC50 > 5000 nM. The effects of chemical modification to groups 
R1 to R4 on the binding to PBBS was studied, including the length of the alkyl chains (R1 and R2), 
the presence of a chloro substituent on position 5 of the indole (R4), and halogen substitution 
(bromine or iodine) on the phenyl ring (R3). The most potent ligands for the PBBS were compounds 
4c and 4k, both displaying IC50 of <10 nM. Decreasing the length of the alkyl chains from hexyl to 
propyl to ethyl, increased the binding affinity for the PBBS. However, compounds with R1 and R2 
as methyl groups had a lower affinity than the compounds with ethyl groups. The compounds with a 
bromo substituent on R3, 4i-l, had higher PBBS affinities than their respective iodo analogues 4a-c, 
and 4e. This suggests that the smaller the halogen on R3, the better the binding affinity. Although no 
direct comparison can be made, compounds reported previously21 with smaller halogen (fluorine 
and chlorine) substituents on R3 appeared to have a higher PBBS binding affinity than compounds 
presented here. It was also reported21 that the optimum alkyl chain length (R1 and R2) for 
compounds with no chloro substituent on R4 were hexyl groups, whereas with the chloro 
substituent, the optimum length was propyl. In this work it was found that compounds with hexyl 
groups had the lowest affinities, with and without a chloro substituent. It was also found that 
affinities increased with the addition of a chloro substituent in compounds containing propyl, ethyl 
or methyl groups.21 Compounds 4e and 4l containing hexyl groups showed higher PBBS affinity 
than compounds 4a and 4i with a chloro group in the R4. This suggests that it is more difficult to 
accommodate the sterically more demanding hexyl groups on molecules with R4 = Cl than in 
compounds with R4 = H, suggesting different molecular orientations are possible.  










Compd R1 R2 R3 R4 Log P a 
Calcd.  





4a hexyl hexyl I Cl > 6 8.29  169 ± 35 18786 ± 1634 
4b propyl propyl I Cl 4.71 ± 0.19 5.78 37.4 ± 6.1 16156 ± 579 
4c ethyl ethyl I Cl 4.00 ± 0.16 4.81 8.23 ± 2.2 15652 ± 45 
4d methyl methyl I  Cl 3.36 ± 0.13 4.13 17.5 ± 4.3 10146 ± 1967 
4e hexyl hexyl I H > 6 7.73  115 ± 22 13803 ± 137  
4f propyl propyl I H 4.00 ± 0.16 5.22 43.6 ± 1.8 14662 ± 127 
4g ethyl ethyl I H 3.27 ± 0.13 4.25 19.1 ± 2.5 13197 ± 2975 
4h methyl methyl I H 2.69 ± 0.11 3.58  618 ± 39   5939 ± 815 
4i hexyl hexyl Br Cl > 6 7.76  138 ± 35 13115 ± 3212 
4j propyl propyl Br Cl 4.56 ± 0.18 5.25 16.7 ± 4.7 10463 ± 2817 
4k ethyl ethyl Br Cl 3.89 ± 0.15 4.28 7.86 ± 1.2 11045 ± 1909 
4l hexyl hexyl Br H > 6 7.20 54.7 ± 22.6 16348 ± 716 
PK 11195      5.30 3.7 ± 1.2 >1,000 
a Estimated by Chem Draw Ultra. 
b The concentration of tested compounds that inhibited [3H]PK11195 binding to rat kidney mitochondrial membranes 
(IC50) by 50% was determined with 6 concentrations of the test compounds, each performed in triplicate. c The 
concentration of tested compounds that inhibited [3H]Flumazenil binding to rat cortex membranes (IC50) by 50% was 
determined with 6 concentrations of the displacers, each performed in triplicate.  
IC50 values are the mean ± SEM derived from at least 2 independent experiments. 
To perform radiolabelling, the corresponding trimethyl stannane 5 was prepared by treatment of the 
bromo derivative 4k with hexamethylditin and palladium tetrakistriphenylphosphine in refluxing 
toluene. [123I]-4c was prepared by electrophilic iododestannylation in the presence of per-acetic acid 
as the oxidant in 55-60% radiochemical yield and above 98% radiochemical purity.  
Lipophilicity measurements of all compounds were assessed in order to explain their in vivo 
properties. As expected the presence of bulky alkyl groups (R1 and R2) greatly influenced the 
overall lipophilicity of the molecules resulting in compounds 4a, 4e, 4i, and 4l having log P values 
greater than 6 and molecules with propyl groups 4b, 4f, 4j greater than 4. In addition, incorporating 
a chloro substituent on R4 increased the log P values from 3.27 in 4g and 2.69 in 4h to 4.0 in 4c and 
3.36 in 4d respectively. However, the presence of small alkyl groups such as ethyl and methyl in the 
R1 and R2 positions and hydrogen in the R4 positions can yield compounds with log P values 
between 2 and 4.  
4. Conclusion 
A series of N,N-dialkyl-2-(4'-iodo- and 4'-bromo-phenylindol-3-ylglyoxylamides 4a-l were 
synthesised and their binding affinity for the PBBS and CBR determined using [3H]PK11195 and 
[3H]Flumazenil on rat kidney mitochondrial and cortical membranes respectively. The brominated 
and iodinated compounds 4c and 4k bearing a chloro-substituent on R4 and ethyl groups at R1 and 
R2 displayed the highest affinity for the PBBS. All compounds displayed low affinity for the CBR 
(IC50> 5000 nM). Compound 4c was radiolabelled with iodine-123 by electrophilic 
iododestannylation using per-acetic acid as the oxidant in 55-60% radiochemical yield and > 98% 
radiochemical purity.  
5. Experimental 
Melting points were determined on a Gallenkamp melting point apparatus and were uncorrected. 
Elemental analyses were performed on a Carlo Erba 1106 Elemental analyser at the Campbell 
Microanalytical Laboratory, University of Otago (Dunedin, New Zealand), and their results are 
within ±0.4% of theoretical values. 1H and 13C nuclear magnetic resonance (NMR) spectra were 
recorded using a Bruker 400 MHz spectrometer. Chemical shifts (δ) are expressed in ppm, and the 
coupling constants (J) in Hz. Signals are recorded as singlet (s), doublet (d), triplet (t), quartet (q) 
and multiplet (m). Mass spectra (MS) were obtained using either a VG Quattro triple quadrupole 
system or an Autospec high-resolution mass spectrometer. Analytical thin layer chromatography 
(TLC) was performed on Merck Kieselgel 60 F254 precoated polyester plates with a thickness of 250 
μm. Column chromatography was performed on Merck Keiselgel 60 (220-440 mesh). Reagents and 
solvents were purchased from commercial sources and were used without further purification. 
Petroleum ether of boiling point range 30-60 °C was used. Yields refer to purified products and are 
not optimised. Chromatographic separation of radiolabelled product was carried out on a 
Phenomenex bondclone semi-preparative RP C-18 column (10 μ, 7.8 mm x 300 mm) using a 
Waters 510 pump, an Activon Linear UV detector set at 254 nm, and an in-line NaI-Berthold 
radioactivity detector. Carrier free Na123I in 0.1M NaOH was obtained from Australian 
Radioisotopes and Industrials (ARI), Australia. 
 [3H]-PK11195 and [3H]-Flumazenil were purchased from Perkin-Elmer Life Sciences (Boston, 
MA, USA). PK11195 and Flumazenil were purchased from Sigma-RBI. For binding studies, male 
Sprague Dawley rats were purchased from Animal Resources Centre (Perth, WA, Australia). All 
procedures were carried out in compliance with Australian laws governing animal experimentation.  
5.1. 4-Iodoacetophenone 4-chlorophenylhydrazone (1a) 
A mixture of 4-iodoacetophenone (4.15 g, 16.9 mmol), 4-chlorophenylhydrazine hydrochloride 
(3.00 g, 16.8 mmol), and a few drops of glacial acetic acid in ethanol (40 mL) was stirred and 
heated at reflux for 45 min. A precipitate that formed was filtered and washed with dilute HCl 
followed by cold 95% ethanol (10 mL). The product was recrystallised in ethanol to yield 1a (3.34 
g, 54%) as yellow crystals: mp 130-132 °C. 1H NMR (CDCl3) δ 2.21 (s, 3H, CH3), 7.11 (d, 2H, J = 
8.9, 2ArH), 7.24 (d, 2H, J = 8.9, 2ArH), 7.34 (bs, 1H, NH), 7.51 (d, 2H, J = 8.6, 2ArH), 7.71 (d, 
2H, J = 8.6, 2ArH). 13C NMR (CDCl3) δ 12.0, 94.2, 114.8, 125.4, 127.7, 129.6, 137.8, 138.8, 141.0, 
144.0. MS (EI) m/z 370 (M+, 33%). Anal. Calcd for C14H12ClIN2: C, 45.37; H, 3.26; N, 7.56. 
Found: C, 45.67; H, 3.37; N, 7.47.  
5.2. 4-Iodoacetophenone phenylhydrazone (1b) 
In similar manner, 4-iodoacetophenone (5.00 g, 20.3 mmol) and phenylhydrazine (2.0 mL, 20.3 
mmol) in ethanol (30 mL) gave 1b (4.38 g, 64%) as orange crystals. 1H NMR (CDCl3) δ 2.19 (s, 
3H, CH3), 6.89 (t, 1H, J = 7.2, ArH4), 7.16 (d, 2H, J = 7.8, 2ArH), 7.28 (m, 2H, 2ArH), 7.52 (d, 2H, 
J = 8.6, 2ArH), 7.68 (d, 2H, J = 8.6, 2ArH). MS (EI) m/z 336 (M+, 100%). 
5.3. 4-Bromoacetophenone 4-chlorophenylhydrazone (1c) 
In a similar manner, 4-bromoacetophenone (6.89 g, 34.6 mmol) and 4-chlorophenylhydrazine 
hydrochloride (6.20 g, 34.6 mmol) in ethanol (60 mL) gave 1c (8.38 g, 75%) as pale yellow 
crystals: mp 132-134 °C. 1H NMR (CDCl3) δ 2.20 (s, 3H, CH3), 7.09 (d, 2H, J = 8.9, 2ArH), 7.23 
(d, 2H, J = 8.9, 2ArH), 7.33 (bs, 1H, NH), 7.49 (d, 2H, J = 8.7, 2ArH), 7.64 (d, 2H, J = 8.7, 2ArH). 
13C NMR (CDCl3) δ 12.1, 114.8, 122.6, 125.4, 127.5, 129.6, 130.2, 131.8, 138.1, 144.0. MS (EI) 
m/z 324 (M+, 74%), 126 (M+ - 198, 100%). Anal. Calcd for C14H12N2ClBr: C, 51.96; H, 3.74; N, 
8.66. Found: C, 52.07; H, 3.59; N, 8.88. 
5.4. 5-Chloro-2-(4-iodophenyl)indole (2a) 
A mixture of 1a (3.10 g, 8.4 mmol) and polyphosphoric acid (20 g) was stirred for 30 min at 110 
°C. Ice water (250 mL) was added and the mixture was stirred. The precipitate was filtered, washed 
with water, and recrystallised from 95% ethanol, to yield 2a (1.66 g, 56%) as a white solid: mp 210-
211 °C. 1H NMR (DMSO-d6) δ 6.92 (s, 1H, H3), 7.10 (dd, 1H, J6,7 = 8.6, J6,4 = 2.0, H6), 7.39 (d, 
1H, J7,6 = 8.6, H7), 7.57, (d, 1H, J4,6 = 1.9, H4), 7.66 (d, 2H, J = 8.4, 2ArH), 7.83 (d, 2H, J = 8.4, 
2ArH), 11.77 (s, 1H, NH). 13C NMR (DMSO-d6) δ 95.4, 100.6, 114.5, 120.9, 123.5, 125.7, 128.8, 
131.3, 132.9, 137.3, 139.4, 139.9. MS (CI) m/z 354 (M+, 34%), 228 (M+ - 126, 100%). Anal. Calcd 
for C14H9ClIN: C, 47.56; H, 2.57; N, 3.96. Found: C, 47.56; H, 2.36; N, 4.18. 
5.5. 2-(4-Iodophenyl)indole (2b)23 
Treatment of a mixture of 1b (3.09 g, 9.19 mmol) and polyphosphoric acid (15 g) at 60-70 °C as 
above gave 2b (1.70 g, 58%) as a white solid. 1H NMR (CDCl3) δ 6.82 (s, 1H, H3), 7.12 (t, 1H, H5 
or H6), 7.21 (t, 1H, H6 or H5), 7.38 (d, 3H, 2ArH and H7), 7.62 (d, 2H, J = 7.8, H4), 7.76 (d, 2H, J 
= 10.8, 2ArH), 8.27 (bs, 1H, NH). 13C NMR (DMSO-d6) δ 94.1, 100.5, 112.5, 120.7, 121.4, 123.1, 
128.1, 129.7, 132.9, 137.7, 138.4, 138.8. MS (EI) m/z 319 (M+, 100%). 
5.6. 2-(4-Bromophenyl)-5-chloroindole (2c)  
Treatment of a mixture of 1c (5.12 g, 15.8 mmol) and polyphosphoric acid (30 g) as above gave 2c 
(3.35 g, 69%) as a pale yellow solid: mp. 206-207 °C. 1H NMR (DMSO-d6) δ 6.91 (s, 1H, H3), 7.11 
(dd, 1H, J6,7 = 8.6, J6,4 = 2.0, H6), 7.40 (d, 1H, J7,6 = 8.6, H7), 7.57 (d, 1H, J4,6 = 1.9, H4), 7.66 (d, 
2H, J = 8.5, 2ArH), 7.80 (d, 2H, J = 8.5, 2ArH), 11.79 (s, 1H, NH). 13C NMR (DMSO-d6) δ 99.0, 
112.8, 119.2, 120.8, 121.8, 124.1, 127.1, 129.7, 130.9, 131.9, 135.7, 138.1. MS (CI) m/z 308 (M+, 
79%), 228 (M+ - 79, 100%). Anal. Calcd for C14H9BrClN: C, 54.85; H, 2.96; N, 4.57. Found: C, 
54.93; H, 3.11; N, 4.50. 
5.7. 2-(4-Bromophenyl)indole (2d)22 
To a mixture of 4-bromoacetophenone (6.89 g, 34.6 mmol) and phenylhydrazine (3.4 mL, 34.6 
mmol) was added polyphosphoric acid (40 g). The reaction mixture was heated at 110 °C, stirring 
occasionally until the mixture turned a deep reddish brown colour. The reaction mixture was 
worked up the same as 2a to yield 2d (5.41 g, 58%) as a white solid. 1H NMR (CDCl3) δ 6.82 (s, 
1H, H3), 7.13 (t, 1H, J = 7.9, H5 or H6), 7.21 (t, 1H, J = 8.2, H6 or H5), 7.39 (d, 1H, J = 8.0, H7), 
7.51 (d, 2H, J = 8.7, 2ArH), 7.56 (d, 2H, J = 8.7, 2ArH), 7.62 (d, 1H, J = 8.0, H4), 8.27 (bs, 1H, 
NH). MS (EI) m/z 271 (79BrM+, 100%), 273 (81BrM+, 98%). HRMS-EI+ calculated for C14H10NBr: 
270.9997, found 270.9995. 
5.8. [5-Chloro-2-(4-iodophenyl)indol-3-yl]glyoxylyl chloride (3a) 
To a partially dissolved solution of indole 2a (0.65 g, 1.84 mmol) in anhydrous diethyl ether at 0 
°C, was added dropwise oxalyl chloride (0.22 mL, 2.57 mmol) and the mixture stirred for 6 h at 
room temperature. The precipitate was collected by filtration and washed with a small portion of 
diethyl ether to yield 3a (0.72 g, 88%) which was directly used to synthesise 4a-d. 1H NMR 
(DMSO-d6) δ 7.33 (d, 1H, J6,7 = 8.6, H6), 7.38 (d, 2H, J = 8.1, 2 x ArH), 7.54 (d, 1H, J7,6 = 8.6, H7), 
7.89 (d, 2H, J = 8.1, 2 x ArH), 8.08 (s, 1H, H4). 
5.9. [2-(4-Iodophenyl)indol-3-yl]glyoxylyl chloride (3b) 
Treatment of 2b (0.39 g, 1.22 mmol) and oxalyl chloride (0.15 mL, 1.70 mmol) in diethyl ether (6.5 
mL) for 1 h as above gave 3b (0.34 g, 68%). 1H NMR (DMSO-d6) δ 7.25 – 7.35 (m, 2H, H5 and 
H6), 7.39 (d, 2H, J = 8.2, 2 x ArH), 7.52 (d, 1H, J7,6 = 7.6, H7), 7.89 (d, 2H, J = 8.2, 2 x ArH), 8.09 
(d, 1H, J4,5 = 7.4, H4), 12.83 (s, 1H, NH). 
5.10. [2-(4-Bromophenyl)-5-chloroindol-3-yl]glyoxylyl chloride (3c) 
Reaction of 2c (1.55 g, 5.06 mmol) and oxalyl chloride (0.62 mL, 7.08 mmol) in diethyl ether (14 
mL) for 4 h gave 3c (1.96 g, 98%). 1H NMR (DMSO-d6) δ 7.34 (dd, 1H, J6,7 = 8.6, J6,4 = 2.1, H6), 
7.38 (d, 2H, J = 8.3, 2 x ArH), 7.54 (d, 1H, J7,6 = 8.6, H7), 7.90 (d, 2H, J = 8.3, 2 x ArH), 8.08 (d, 
1H, J4,6 = 2.0, H4), 12.84 (s, 1H, NH). 
5.11. [2-(4-Bromophenyl)indol-3yl]glyoxylyl chloride (3d) 
Reaction of 2d (2.00 g, 7.35 mmol) and oxalyl chloride (0.90 mL, 10.3 mmol) in diethyl ether (20 
mL) for 1 h gave 3d (1.75 g, 66%). 1H NMR (CDCl3) δ 7.37-7.41 (m, 2H, H5 and H6), 7.42 (d, 2H, 
J = 8.5, 2 x ArH), 7.44-7.49 (m, 1H, H7), 7.66 (d, 2H, J = 8.5, 2 x ArH), 8.24-8.29 (m, 1H, H4), 
8.92 (bs, 1H, NH). 
5.12. N,N-Dihexyl-[5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylamide (4a) 
To a solution of the chloride 3a (0.30 g, 0.67 mmol) and triethylamine (0.11 mL, 0.81 mmol) in 
anhydrous toluene (30 mL) at 0 °C was added dropwise a solution of dihexylamine (0.17 mL, 0.74 
mmol) in anhydrous toluene (20 mL). The solution was stirred at room temperature for 24 h. The 
solution was filtered and the filtrate was washed sequentially with 0.5 M HCl, saturated NaHCO3, 
and water. The combined organic extracts were dried with MgSO4, filtered, and the solvent was 
evaporated. The crude product was purified by column chromatography (methanol/chloroform, 1:19 
v/v), then recrystallised (ethyl acetate/petroleum ether, 1:9 v/v) to give 4a (0.12 g, 30%) as a white 
solid: mp 108–110 °C. 1H NMR (DMSO-d6) δ 0.75 (t, 3H, CH3), 0.88 (t, 3H, CH3), 1.00-1.20 (m, 
10H, 5CH2), 1.21-1.35 (m, 4H, 2CH2), 1.36-1.46 (m, 2H, CH2), 2.94-3.08 (m, 4H, 2NCH2), 7.32 
(dd, 1H, J6,7 = 8.7, J6,4 = 1.8, H6), 7.37 (d, 2H, J = 8.1, 2 x ArH), 7.50 (d, 1H, J7,6 = 8.7, H7), 7.88 
(d, 2H, J = 8.1, 2 x ArH), 8.04 (s, 1H, H4), 12.68 (bs, 1H, NH). 13C NMR (DMSO-d6) δ 15.4, 15.6, 
23.5, 23.7, 27.2, 27.9, 28.1, 29.3, 32.3, 32.8, 45.4, 48.9, 98.7, 111.0, 115.5, 121.7, 125.3, 128.9, 
129.5, 131.4, 133.5, 136.0, 138.6, 148.9, 168.6, 188.6. MS (EI) m/z 592 (M+, 3%), 380 (M+ - 212, 
100%). HRMS-ES calculated for C28H35ClIN2O2: 593.1432, found 593.1470. Anal. Calcd for 
C28H34ClIN2O2: C, 56.72; H, 5.78; N, 4.72. Found: C, 56.49; H, 5.75; N, 4.72.   
5.13. N,N-Di-n-propyl-[5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylamide (4b) 
Reaction of 3a (0.72 g, 1.62 mmol) and di-n-propylamine (0.25 mL, 1.78 mmol) for 7 h as above 
gave after trituration with petroleum ether, 4b (0.47 g, 57%) as an off-white solid: mp 148-150 °C. 
1H NMR (DMSO-d6) δ 0.69 (t, 3H, J = 7.4, CH3), 0.78 (t, 3H, J = 7.4, CH3), 1.12-1.28 (m, 2H, 
CH2), 1.40-1.50 (m, 2H, CH2), 2.95 (t, 2H, J = 7.8, NCH2), 3.01 (t, 2H, J = 7.7, NCH2), 7.31 (dd, 
1H, J6,7 = 8.6, J6,4 = 2.1, H6), 7.35 (d, 2H, J = 8.3, 2 x ArH), 7.51 (d, 1H, J7,6 = 8.6, H7), 7.87 (d, 2H, 
J = 8.3, 2 x ArH), 8.02 (d, 1H, J4,6 = 1.9, H4). 13C NMR (DMSO-d6) δ 12.5, 13.1, 21.6, 22.8, 47.2, 
50.8, 98.6, 111.1, 115.5, 121.6, 125.3, 128.9, 129.5, 131.4, 133.4, 136.0, 138.6, 149.0, 168.8, 188.5. 
MS (ES) m/z 509 (M+1, 88%), 106 (100%). HRMS-ES calculated for C22H23ClIN2O2: 509.0493, 
found 509.0524. Anal. Calcd for C22H22ClIN2O2: C, 51.94; H, 4.36; N, 5.51. Found: C, 52.14; H, 
4.58; N, 5.53. 
5.14. N,N-Diethyl-[5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylamide (4c) 
Reaction of 3a (0.36 g, 0.80 mmol) and diethylamine (0.09 mL, 0.88 mmol) for 19 h yielded after 
column chromatography (ethyl acetate/ petroleum ether, 1:1 v/v) 4c (0.14 g, 36%) as colourless 
crystals: mp 221-222 °C. 1H NMR (DMSO-d6) δ 0.83 (t, 3H, J = 7.1, CH3), 1.02 (t, 3H, J = 7.0, 
CH3), 3.07 (q, 2H, J = 7.1, CH2), 3.15 (q, 2H, J = 7.0, CH2), 7.32 (dd, 1H, J6,7 = 8.6, J6,4 = 2.1, H6), 
7.37 (d, 2H, J = 8.3, 2 x ArH), 7.51 (d, 1H, J7,6 = 8.6, H7), 7.88 (d, 2H, J = 8.3, 2 x ArH), 8.05 (d, 
1H, J4,6 = 2.0, H4). 13C NMR (DMSO-d6) δ 12.5, 14.1, 38.4, 42.2, 97.4, 109.8, 114.3, 120.5, 124.1, 
127.7, 128.4, 130.3, 132.3, 134.8, 137.3, 147.9, 167.1, 187.4. MS (ES) m/z 478 (M-1, 100%). 
HRMS-ES calculated for C20H19ClIN2O2: 481.0180, found 481.0180. Anal. Calcd for 
C20H18ClIN2O2: C, 49.97; H, 3.77; N, 5.83. Found: C, 50.27; H, 4.05; N, 5.85. 
5.15. N,N-Dimethyl-[5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylamide (4d) 
Dimethylamine (30 mL, 40% wt/vol in water) was gently heated and under constant N2 pressure 
bubbled through NaOH pellets into a solution of 3a (0.65 g, 1.46 mmol) in toluene. After 
purification by column chromatography (ethyl acetate/ petroleum ether, 1:1 v/v) and trituration with 
ethyl acetate/ petroleum ether, 3:7 v/v, 4d (65 mg, 10%) was obtained as a solid: mp 238 °C 
(decomposed). 1H NMR (DMSO-d6) δ 2.45 (s, 3H, NCH3), 2.79 (s, 3H, NCH3), 7.32 (d, 2H, J = 
8.3, 2 x ArH), 7.33 (dd, 1H, J6,7 = 8.6, H6), 7.52 (d, 1H, J7,6 = 8.6, H7), 7.91 (d, 2H, J = 8.3, 2 x 
ArH), 8.11 (d, 1H, J = 2.0, H4). 13C NMR (DMSO-d6) δ 33.7, 37.4, 97.9, 110.6, 114.8, 121.1, 
124.7, 128.3, 128.8, 130.6, 132.5, 135.3, 137.7, 148.8, 167.5, 188.1. MS (ES) m/z 453 (M+1, 21%), 
338 (M-114, 100%). HRMS-ES calculated for C18H15ClIN2O2: 452.9867, found 452.9872. Anal. 
Calcd for C18H14ClIN2O2: C, 47.76; H, 3.12; N, 6.19. Found: C, 47.54; H, 3.39; N, 5.89. 
 
5.16. N,N-Dihexyl-2-(4-iodophenyl)indol-3-ylglyoxylamide (4e) 
Reaction of 3b (0.23 g, 0.56 mmol) and dihexylamine (0.15 mL, 0.62 mmol) for 18 h followed by 
column chromatography (ethyl acetate/ petroleum ether, 2:3 v/v) and recrystallisation (ethanol/ 
water) gave 4e (0.10 g, 32%) as a white solid: mp 120-122 °C. 1H NMR (DMSO-d6) δ 0.74 (t, 3H, J 
= 7.0, CH3), 0.84 (t, 3H, J = 6.9, CH3), 1.00-1.45 (m, 16H, 8CH2), 2.95-3.07 (m, 4H, 2NCH2), 7.21-
7.31 (m, 2H, H5 and H6), 7.37 (d, 2H, J = 8.3, 2 x ArH), 7.48 (d, 1H, J = 7.7, H7), 7.87 (d, 2H, J = 
8.3, 2 x ArH), 8.04 (d, 1H, J = 7.7, H4). 13C NMR (DMSO-d6) δ 13.8, 14.0, 21.8, 22.1, 25.6, 26.2, 
26.4, 27.5, 30.6, 31.1, 43.7, 47.3, 96.7, 109.8, 112.1, 120.9, 122.5, 123.6, 126.7, 130.2, 131.9, 
135.8, 136.8, 146.0, 167.3, 187.1. MS (EI) m/z 558 (M+, 4%), 346 (M+ - 212, 100%). HRMS-EI 
calculated for C28H35N2O2I: 558.1743, found 558.1747. 
5.17. N,N-Di-n-propyl-2-(4-iodophenyl)indol-3-ylglyoxylamide (4f) 
Reaction of 3b (0.23 g, 0.56 mmol) and di-n-propylamine (0.09 mL, 0.62 mmol) for 20 h, followed 
by column chromatography (ethyl acetate/ petroleum ether, 1:1 v/v) and trituration with ethyl 
acetate/ petroleum ether, 3:7, v/v, gave 4f (58.2 mg, 22%) as an off-white solid: mp 159-161 °C. 1H 
NMR (DMSO-d6) δ 0.69 (t, 3H, J = 7.4, CH3), 0.79 (t, 3H, J = 7.4, CH3), 1.13-1.25 (m, 2H, CH2), 
1.41-1.52 (m, 2H, CH2), 2.96 (t, 2H, J = 7.9, NCH2), 3.03 (t, 2H, J = 7.7, NCH2), 7.21-7.33 (m, 2H, 
H5 and H6), 7.37 (d, 2H, J = 8.4, 2 x ArH), 7.48 (d, 1H, J = 7.3, H7), 7.88 (d, 2H, J = 8.4, 2 x 
ArH), 8.03 (d, 1H, J = 7.3, H4). 13C NMR (DMSO-d6) δ 11.9, 12.4, 20.9, 22.2, 46.5, 50.2, 97.6, 
110.8, 113.1, 121.8, 123.5, 124.5, 127.6, 131.3, 132.9, 136.8, 137.8, 147.0, 168.4, 188.0. MS (EI) 
m/z 474 (M+, 6%), 346 (M+ - 128, 100%). HRMS-EI calculated for C22H23N2O2I: 474.0804, found 
474.0795. 
5.18. N,N-Diethyl-[2-(4-iodophenyl)indol-3-yl]glyoxylamide (4g) 
Reaction of 3b (0.14 g, 0.34 mmol) and diethylamine (0.05 mL, 0.47 mmol) for 3 h gave after 
recrystallisation (ethyl acetate / petroleum ether, 1:1 v/v) 4g (60 mg, 40%) as off-white crystals: mp 
169-171 °C. 1H NMR (DMSO-d6) δ 0.85 (t, 3H, J = 7.1, CH3), 1.02 (t, 3H, J = 7.0, CH3), 3.07 (q, 
2H, J = 7.1, NCH2), 3.15 (q, 2H, J = 7.0, NCH2), 7.22-7.32 (m, 2H, H5 and H6), 7.37 (d, 2H, J = 
8.3, 2 x ArH), 7.49 (d, 1H, J = 7.3, H7), 7.87 (d, 2H, J = 8.3, 2 x ArH), 8.06 (d, 1H, J = 7.2, H4). 
13C NMR (DMSO-d6) δ 13.8, 15.3, 39.5, 43.5, 98.3, 111.5, 113.8, 122.5, 124.2, 125.3, 128.4, 131.9, 
133.6, 137.3, 138.4, 147.7, 168.7, 188.8. MS (ES) m/z 445 (M-1, 100%). HRMS-EI calculated for 
C20H19IN2O2: 446.0491, found 446.0489. Anal. Calcd for C20H19IN2O2: C, 53.83; H, 4.29; N, 6.28. 
Found: C, 53.50; H, 4.41; N, 6.11. 
5.19. N,N-Dimethyl-[2-(4-iodophenyl)indol-3-yl]glyoxylamide (4h) 
Dimethylamine (30 mL, 40% wt/vol in water) was gently heated and under constant N2 pressure 
bubbled through NaOH pellets into a solution of 3b (0.30 g, 0.73 mmol) in toluene. After column 
chromatography (ethyl acetate/ petroleum ether, 1:1 v/v), 4h was obtained (14 mg, 5%) as an off-
white solid: mp 231-232 °C. 1H NMR (DMSO-d6) δ 2.49 (s, 3H, NCH3), 2.79 (s, 3H, NCH3), 7.20-
7.30 (m, 2H, H5 and H6), 7.34 (d, 2H, J = 8.1, 2 x ArH), 7.48 (d, 1H, J = 7.0, H7), 7.89 (d, 2H, J = 
8.3, 2 x ArH), 8.07 (d, 1H, H4). 13C NMR (DMSO-d6) δ 34.4, 38.1, 98.0, 111.3, 114.0, 122.5, 
124.3, 125.2, 128.2, 130.5, 133.3, 138.2, 168.8, 187.2. MS (EI) m/z 418 (M+, 6%), 346 (M+ - 72, 
100%). HRMS-EI calculated for C18H15N2O2I: 418.0178, found 418.0161. Anal. Calcd for 
C18H15IN2O.H2O: C, 49.56; H, 3.93; N, 6.42. Found: C, 49.70; H, 3.46; N, 6.29 
5.20. N,N-Dihexyl-[2-(4-bromophenyl)-5-chloroindol-3-ylglyoxylamide (4i) 
Reaction of 3c (0.46 g, 1.16 mmol) and dihexylamine (0.30 mL, 1.27 mmol) for 7 h, followed by 
purification by column chromatography (ethyl acetate/ petroleum ether, 2:3 v/v) and 
recrystallisation (ethyl acetate/ petroleum ether, 1:9 v/v) gave 4i (0.20 g, 32%) as a white solid: mp 
103-105 °C. 1H NMR (DMSO-d6) δ 0.77 (t, 3H, J = 7.0, CH3), 0.87 (t, 3H, J = 6.8, CH3), 1.00 – 
1.46 (m, 16H, 8CH2), 2.95 – 3.09 (m, 4H, 2NCH2), 7.32 (dd, 1H, J6,7 = 8.6, J6,4 = 2.0, H6), 7.51 (d, 
1H, J7,6 = 8.7, H7), 7.54 (d, 2H, J = 8.4, 2 x ArH) 7.72 (d, 2H, J = 8.4, 2 x ArH), 8.03 (s, 1H, H4). 
13C NMR (DMSO-d6) δ 14.7, 14.9, 22.8, 23.0, 26.5, 27.1, 27.4, 28.6, 31.6, 32.0, 44.7, 48.2, 110.4, 
114.8, 121.0, 124.5, 124.6, 128.1, 128.7, 130.4, 132.0, 132.9, 135.3, 148.0, 167.9, 187.8. MS (EI) 
m/z 546 (M+, 1%), 334 (M+ - 212, 100%). HRMS-EI calculated for C28H3481Br37ClN2O2: 548.1442, 
found 548.1442. Anal. Calcd for C28H34BrClN2O2: C, 61.60; H, 6.28; N, 5.13. Found: C, 61.35; H, 
6.02; N, 5.06. 
5.21. N,N-Di-n-propyl-[2-(4-bromophenyl)-5-chloroindol-3-ylglyoxylamide (4j) 
Reaction of 3c (0.41 g, 1.03 mmol) and di-n-propylamine (0.16 mL, 1.13 mmol) for 24 h, followed 
by purification by column chromatography (ethyl acetate/ petroleum ether, 1:1 v/v) and 
recrystallisation (diethyl ether/ petroleum ether) gave 4j (0.25 g, 53%) as a white solid: mp 128-129 
°C. 1H NMR (DMSO-d6) δ 0.69 (t, 3H, J = 7.4, CH3), 0.77 (t, 3H, J = 7.4, CH3), 1.15-1.25 (q, 2H, J 
= 7.8, CH2), 1.40-1.50 (q, 2H, J = 7.6, CH2), 2.96 (t, 2H, J = 7.8, NCH2), 3.02 (t, 2H, J = 7.7, 
NCH2), 7.31 (dd, 1H, J6,7 = 8.6, J6,4 = 2.1, H6), 7.51 (d, 1H, J7,6 = 8.7, H7), 7.52 (d, 2H, J = 8.5, 2 x 
ArH), 7.70 (d, 2H, J = 8.5, 2 x ArH), 8.00 (dd, 1H, J4,6 = 1.74, H4). 13C NMR (DMSO-d6) δ 11.5, 
12.0, 20.6, 21.8, 46.2, 49.9, 110.1, 114.6, 120.6, 124.2, 124.3, 127.9, 128.4, 130.2, 131.7, 132.5, 
135.0, 147.8, 167.8, 187.4. MS (ES) m/z 463 (81Br M+1, 61%), 106 (M - 357, 100%). HRMS-ES 
calculated for C22H23N2O2ClBr 461.0631, found 461.0649. Anal. Calcd for C22H22BrClN2O2: C, 
57.22; H, 4.80; N, 6.07. Found: C, 57.33; H, 4.89; N, 6.01. 
5.22. N,N-Diethyl-[2-(4-bromophenyl)-5-chloroindol-3-ylglyoxylamide (4k) 
To a solution 3c (0.72 g, 1.81 mmol) in anhydrous toluene (40 mL) at 0 °C was added dropwise a 
solution of triethylamine (0.30 mL, 2.18 mmol) and diethylamine (0.21 mL, 1.99 mmol) in 
anhydrous toluene (10 mL). The reaction mixture was stirred at room temperature for 18 h. A white 
precipitate that formed was filtered, washed with water (25 mL) and extracted into dichloromethane 
(2 x 40 mL). The combined organic extracts were dried with MgSO4, filtered, and the solvent 
evaporated in vacuo. After recrystallisation (ethyl acetate/ petroleum ether, 1:1 v/v) 4k (0.462 g, 
59%) was obtained as a white solid: mp 216-217 °C. 1H NMR (DMSO-d6) δ 0.84 (t, 3H, J = 7.1, 
CH3), 1.02 (t, 3H, J = 7.0, CH3), 3.07 (q, 2H, J = 6.9, NCH2), 3.15 (q, 2H, J = 6.8, NCH2), 7.32 (d, 
1H, J = 8.6, H6), 7.47-7.56 (m, 3H, 2 x ArH and H7), 7.72 (d, 2H, 2 x ArH), 8.05 (s, 1H, H4). 13C 
NMR (DMSO-d6) δ 13.0, 14.6, 38.9, 42.7, 110.4, 114.9, 121.0, 124.5, 124.6, 128.1, 128.9, 130.1, 
132.0, 132.9, 135.3, 148.5, 167.7, 188.0. MS (EI) m/z 434 (M+, 4%), 334 (M+ - 100, 100%). Anal. 
Calcd for C20H18BrClN2O2: C, 55.38; H, 4.18; N, 6.46. Found: C, 55.37; H, 4.36; N, 6.40. 
5.23. N,N-Dihexyl-[2-(4-bromophenyl)indol-3-yl]glyoxylamide (4l) 
Reaction of 3d (0.96 g, 2.65 mmol) and dihexylamine (0.68 mL, 2.91 mmol) for 24 h gave after 
purification by column chromatography (methanol/ dichloromethane, 1:19 v/v) and recrystallisation 
(ethanol/ water), 4l (0.62 g, 46%) as a white solid: mp 106–110 °C. 1H NMR (DMSO-d6) δ 0.74 (t, 
3H, J = 7.0, CH3), 0.88 (t, 3H, J = 6.9, CH3), 1.00-1.20 (m, 10H, 5CH2), 1.20-1.30 (m, 4H, 2CH2), 
1.35-1.47 (m, 2H, CH2), 2.95-3.08 (m, 4H, 2NCH2), 7.21-7.32 (m, 2H, H5 and H6), 7.48 (d, 1H, J = 
7.6, H7), 7.53 (d, 2H, J = 8.4, 2 x ArH), 7.70 (d, 2H, J = 8.4, 2 x ArH), 8.05 (d, 1H, J = 7.8, H4), 
12.49 (s, 1H, NH). 13C NMR (DMSO-d6) δ 15.4, 15.6, 23.5, 23.7, 27.2, 27.8, 28.1, 29.4, 32.3, 32.7, 
45.4, 49.0, 111.5, 113.8, 122.6, 124.2, 124.9, 125.3, 128.3, 131.6, 132.6, 133.7, 137.4, 147.4, 168.9, 
188.8. MS (CI) m/z 511 (79Br M+, 4%), 513 (81Br M+, 3%), 298 (79Br M+ - 213, 100%), 300 (81Br 
M+ - 213, 80%). HRMS-EI calculated for C28H35BrN2O2: 510.1882, found 510.1874. Anal. Calcd 
for C28H35BrN2O2: C, 65.75; H, 6.90; N, 5.48. Found: C, 65.64; H, 6.78; N, 5.49. 
5.24. N,N-Diethyl-[2-(4-trimethylstannyl)-5-chloroindol-3-ylglyoxyl]amide (5) 
To a solution of 4k (112 mg, 0.259 mmol) in anhydrous toluene (8 mL) was added hexamethylditin 
(230 μg, 0.702 mmol) and a catalytic amount of Pd(0)(PPh3)4. The reaction mixture was heated at 
reflux under a nitrogen atmosphere for 8 hours. The reaction mixture was passed through celite and 
the solvent evaporated. The product was purified by column chromatography (ethyl acetate: 
petroleum ether, 1:1 v/v) to yield 123I-4c as a white solid (42.7 mg, 32%). 1H NMR (CD3OD) δ 0.36 
(s, 9H, Sn(CH3)3), 0.79 (t, 3H, J = 7.2, CH3), 1.15 (t, 3H, J = 7.2, CH3), 3.07 (q, 2H, J = 7.2, 
NCH2), 3.24 (q, 2H, J = 7.2, NCH2), 7.32 (dd, 1H, J6,7 = 8.4, J6,4 = 2.0, H6), 7.47 (d, 1H, J6,7 = 8.4, 
H7), 7.54 (d, 2H, J = 8.0, 2ArH), 7.65 (d, 2H, J = 8.0, 2ArH), 8.27 (d, 1H, J4,6 = 2.0, H4). MS-ES 
m/z 517 (M-1, 70%). HRMS-ES calculated for C23H28N2O2Cl116Sn: 515.0857, found 515.0903. 
5.25. [123I]-N,N-Diethyl-[5-chloro-2-(4-iodophenyl)indol-3-ylglyoxyl]amide 
To a solution of stannane, 5 (125 μg in ethanol (50 μL) and acetic acid (200 μL)) was added Na123I 
(311 – 544 MBq) and per-acetic acid (30%, 25 μL). After 5 min at room temperature, the reaction 
was quenched with Na2S2O5 (51 mg/mL, 100 μL) and NaHCO3 (48 – 51 mg/mL, 100 μL). Mobile 
phase (acetonitrile/ 0.01M ammonium acetate, 3:2 v/v, 350 μL) was added and the solution was 
injected onto a semi-preparative C-18 RP HPLC column. The retention time at a flow rate of 3 
mL/min was 16 min. The radiochemical purity was > 96% after formulation in saline. 
5.26. Lipophilicity Measurements 
Samples were analysed using a C18 column (X-Terra, 5μ, 4.6 x 250 mm) and a mobile phase of 
methanol and 0.1M phosphate buffer (65:35 v/v, pH = 7.5) with a flow rate of 1 mL/min.24 The log 
P values were estimated by comparing HPLC retention times (RT) of test compounds with retention 
times of standards having known log P values. The standards used were aniline, benzene, 
bromobenzene, ethylbenzene and trimethylbenzene. A calibration curve of log P vs. ln RT was 
generated. The equation was linear with an r2 of 0.9969. Calculated log P values were found using 
Chem Draw Ultra.  
5.27. In vitro Binding Studies 
5.27.1. Peripheral Benzodiazepine Binding Sites. Mitochondrial membranes were prepared from 
kidney extracts sourced from male Sprague Dawley rats. The kidneys were removed, rinsed with 
ice-cold 50 mM Tris-HCl buffer (pH 7.4), weighed and finely cut. After the addition of 20 volumes 
of ice-cold buffer, the preparation was homogenised and the suspension was centrifuged at 49,000 g 
for 15 min at 4 °C. The pellets were resuspended in buffer to achieve a protein concentration of 4 
mg/mL. Membranes were stored at -80 oC until required.25,26 Protein content in the membrane 
suspensions was measured according to a colorimetric method.27 For determination of the inhibition 
constant (IC50), assays were run in triplicate with concentrations of test compounds ranging from 
10-5 to 10-10 M in 50 mM Tris-HCl at pH 7.4 in the presence of [3H]-PK11195 (2 nM) at a final 
protein concentration of 250 µg/mL in a final volume of 0.5 mL. Non-specific binding was 
determined using PK11195 (10 µM), a selective PBBS ligand. Samples were incubated for 1 h at 4 
°C then filtered under reduced pressure on glass fibre filters (Whatman GF/B) pre-soaked in 50 mM 
Tris-HCl. After incubation, filters were immediately washed 4 times with 4 mL ice-cold Tris/HCl 
buffer and the radioactivity remaining on the filters was measured in a β-scintillation counter 
(Packard). IC50 values were calculated using an iterative non-linear least squared curve fitting 
program (Kell Radioligand).  
5.27.2. Central Benzodiazepine Receptor. Cortical membranes were extracted from male Sprague 
Dawley rats. The cortex was removed, rinsed with ice-cold 50 mM Tris-HCl buffer (pH 7.4), 
weighed and finely cut. After the addition of 20 volumes of ice-cold buffer, the preparation was 
homogenised and the suspension was centrifuged at 20,000 g for 20 min at 4 °C. The pellets were 
resuspended in buffer and centrifuged as above. The pellet was resuspended in 50 mM Tris-HCl, 
0.32 M sucrose buffer (pH 7.4) to achieve a protein concentration of 4 mg/mL, and the membranes 
were stored at -80 oC until required. For determination of the inhibition constant (IC50), assays were 
run as for PBBS binding but using [3H]Flumazenil (2 nM) and cortex membranes at a final 
concentration of 250 µg/mL. Samples were incubated for 45 min at 25 oC. Non-specific binding was 
determined using Flumazenil (20 µM), a selective CBR ligand. 
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